Access cutting-edge breast cancer treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.
Access breast cancer specialists in Philadelphia at no cost
This study follows strict safety protocols and ethical guidelines
All study-related breast cancer treatment provided free
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).
Sponsor: Avenzo Therapeutics, Inc.
Check if you qualify for this breast cancer clinical trial in Philadelphia, PA
If you're searching for breast cancer treatment options in Philadelphia, PA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.